Among treatment modalities for lung cancer, the most promising therapy is the use of
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

Introduction: Epidermal growth factor receptor-tyrosine kinase inhibitors are used as
effective first-line and salvage therapy in the treatment of advanced non-small cell lung …

Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …

Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …

7551 Background: Gefitinib and erlotinib are potent inhibitors of the epidermal growth factor
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …

Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Malignant cancer is the top cause of mortality in Taiwan. In particular, the mortality rate of
with lung cancer reached 39.2/100,000 in 2017. Epidermal growth factor receptor tyrosine …